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Abstract: Arsenic, a naturally occurring metalloid derived from the environment, has been studied
worldwide for its causative effects in various cancers. However, the effects of arsenic toxicity on the
development and progression of metabolic syndrome, including obesity and diabetes, has received
less attention. Many studies suggest that metabolic dysfunction and autophagy dysregulation of
adipose and muscle tissues are closely related to the development of metabolic disease. In the USA,
arsenic contamination has been reported in some ground water, soil and grain samples in major
agricultural regions, but the effects on adipose and muscle tissue metabolism and autophagy have
not been investigated much. Here, we highlight arsenic toxicity according to the species, dose and
exposure time and the effects on adipose and muscle tissue metabolism and autophagy. Historically,
arsenic was used as both a poison and medicine, depending on the dose and treatment time. In the
modern era, arsenic intoxication has significantly increased due to exposure from water, soil and food,
which could be a contributing factor in the development and progression of metabolic disease. From
this review, a better understanding of the pathogenic mechanisms by which arsenic alters metabolism
and autophagy regulation could become a cornerstone leading to the development of therapeutic
strategies against arsenic-induced toxicity and metabolic disease.
Keywords: arsenic; adipose; muscle; autophagy; oxidative stress; mitochondrial dysfunction;
metabolism; metabolic syndrome; metabolic disease
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1. Introduction: Arsenic’s Impacts on Food and Human Health in the USA
US citizens consume significant amounts of agricultural products (e.g., rice grain from
California or vegetables and fruits from Michigan) produced from the states with high
exposure levels of arsenic (As) contamination [1–3]. This could correlate with the metabolic
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dysfunction caused by As accumulation in adipose (fat) and muscle tissues of the human
body. For example, in Nebraska, the highest concentrations of As in groundwater, measured
at over 20 µg/L (ppb), were found in the panhandle, southwestern region and Republican
River valley [4], which belong to the Ogallala Aquifer in the Great Plains [5]. Nebraska is
one of the largest beef-producing states, along with having high levels of corn and soybean
production [6]. According to the United States Department of Agriculture (USDA) and
Food and Drug Administration (FDA), As levels in beef, corn and soybean are quite low and
no health concern has been found for most of Nebraska. Since cow livestock are fed with
corn and soybeans and consume water from underground sources, there is still a possibility
of a certain level of As accumulation in beef, corn and soybeans due to As contents in water
and soil in highly As-contaminated areas. Indeed, multiple studies indicate that corn and
soybeans are very susceptible to As uptake in highly As-contaminated areas [7,8]. Since beef
mostly consists of fat and muscle tissues, measurements of As accumulation traveling from
water and soil through to corn and soybeans, beef and finally to humans are increasingly
sought, although there is no accurate database available due to various technical limitations
in the measurement of live animals and humans in highly As-contaminated areas. These
data relate to the USA as a whole, as the prevalence of As contamination in food production
poses a significant concern due to the impacts on human health.
As, a group 1A carcinogen, is a worldwide public health concern; exposure causes
lung, bladder and non-melanoma skin cancers in humans [9–11]. However, in contrast
to extensive research on its carcinogenicity, considerably less studies are available on the
impacts of As exposure on the onset and progression of other prevalent diseases, such as
metabolic and degenerative diseases [12–14]. This is a critical knowledge gap, as several
studies have suggested an association between chronic exposure of high-dose As and
metabolic complications such as obesity and type 2 diabetes mellitus (T2DM), including
from human studies in Michigan and population studies in high-arsenic areas (≥150 µg/L
or ppm in drinking water) in Chile, Taiwan and Bangladesh [1–3,15–18].
A recent study estimated that about 2.1 million people in the USA alone are exposed
to wells or underground water that is high in As [19]. Excess body weight and obesity combined make up the second leading cause of death in the USA [20]. The combined medical
costs associated with the treatment of preventable obesity-associated diseases are estimated
to increase by $48–$66 billion per year by 2030 in the USA [21,22]. It is important to note
that obesity is often associated with dysplasia, lipodystrophy and malfunction of adipose
tissue [17,23]. Disruption of glucose metabolism and accumulation of oxidative stress in
the muscle [24,25] also significantly contribute to the development of metabolic diseases.
Nevertheless, studies on the effects of As on adipose and muscle tissue metabolism, which
are tightly linked to obesity and metabolic diseases, are limited. A better understanding of
As’s instigating roles in metabolic dysfunction in adipose and muscle tissues could lead
to innovative prevention and treatment strategies for people with obesity and metabolic
diseases living in As-contaminated areas.
2. As Biochemistry and Metabolism: Biotransformation of As in the Body
As is a metalloid with an atomic number of 33 that is naturally found in the environment. As compounds can be classified into inorganic, organic and gas states. Inorganic As
is generally considered more toxic than the organic form, while the gas form of As (Arsine)
is the most toxic arsenical when acutely exposed in high concentrations [26]. As originates
from the earth’s crust and is present at high levels in groundwater [27]. Humans can
be exposed to As most significantly from contaminated groundwater by drinking, and
indirectly at lower amounts from food (crops, fish, meat and dairy products prepared
with As-contaminated water), industrial processes (alloying agents, metal adhesives, wood
preservatives, pesticides, pharmaceuticals, etc.) or tobacco via cigarette smoking [28].
As can enter into the human body via ingestion through the gastrointestinal (GI) tract,
inhalation through the lungs and dermal absorption. Absorbed inorganic As is metabolized
in the human body with a half-life of two to four days [29], and approximately 60–80%
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of As is excreted in the urine through the kidneys within a few days of ingestion [30]. After
absorption through the GI tract and lungs, As is taken up by red and white blood cells
in the bloodstream first before reaching the liver [31].
Accumulated As in the body can generate ROS and epigenetic dysregulation, which
promotes carcinogenesis. One study reported that the Rac family small GTPase 1 (Rac1) signaling pathway mediates As-induced generation of reactive oxygen species (ROS), which
are well-known second messengers for cellular pathogenic effects by damaging protein,
DNAs and organelles. Rac1 is an essential subunit of NADPH oxidase isoform Nox2, which
is required for As-stimulated vessel remodeling during carcinogenesis [32,33]. Recent work
found the links between As exposure to epigenetic dysregulation and progression of the
pathology. During carcinogenesis, As exposure induces a loss of DNA methylation, which
increases gene expression [34,35]. Arsenic-induced malignant transformations in human
urothelial cells are associated with an aberrant DNA methylation increased by As exposure [36]. Therefore, the detoxification and secretion of absorbed As out of the body is the
critical process in As biotransformation in order to remedy the toxicity.
The most efficient detoxification process of As in the human body is through methylation. As methylation is a biotransformation conserved from bacteria to humans to
modulate As toxicity and carcinogenicity [37–39]. This process is catalyzed through
S-adenosylmethionine (SAM)—dependent methyltrasferase (MT), which is encoded by
the arsM gene [37,40]. Arsenate (AsV ) can be reduced to arsenite (AsIII ) or methylated
in the liver via enzymatic transfer of the methyl group from SAM to methyl arsonate
(MMAV ) and dimethyl arsenate (DMAV ). However, methylation of inorganic As such as
monomethylarsonous acid (MMAIII ) and dimethylarsinous acid (DMAIII ) would be toxic
when interacting with cellular proteins and DNA [41,42]. When the methylating capacity
of the liver is exceeded, As can be retained for two to four weeks or longer in soft tissues,
including adipose and muscle tissues, as well as in keratin-rich tissues, including hair, nail
and skin tissues [43,44].
As can be reduced by the antioxidant glutathione (GSH). As binding to the thiol (SH-)
group is very strong and the reduction is initiated by shifts in the carbon atom bonded to the
sulfhydryl group of the cysteinyl residue of GSH [45]. Dietary selenium (Se) compounds
and α–tocopherol (Vitamin E) protect human cells and mice from As-induced mutagenesis
and carcinogenesis [46].
Methylated trivalent inorganic As in the liver is released into the bloodstream and
excreted in urine via transport through cell membranes. The groups of uptake and efflux
channels facilitate As species transport, namely prokaryotic phosphate transporters (Pit
and Pts); GlpF (glycerol facilitator protein) from Escherichia coli; AqpS (aquaporin) from
Sinorhizobium meliloti); HxP (hexose permease) and Fps1p (yeast aquaglyceroporin) from
Saccharomyces cerevisiae; and mouse aquaporin (AQP) 7, rat and human AQP9, glucose
transporter (GLUT) 1 from mammals [47,48]. Additionally in mammals, GLUT2 and
multidrug-resistance-associated protein (MRP) 2 play an important role in the efflux of
dimethylarsenic metabolites (DMAs) [49,50]. These studies indicate that As transporters
in each species have evolutionarily significant differences both in selectivity and transport
rates of arsenicals.
Recently, there has been an emerging interest in the thiolation of As, which is a naturally occurring chemical reaction via adsorption on iron oxides and precipitation on
iron sulfide minerals [51] and was found in geothermal waters in Yellowstone National
Park [52] and in soil pore waters in rice fields [53,54]. The increasing synthesis and detection of thioarsenic species such as monomethylmonothioarsonous acid (MMMTAIII ),
dimethylmonothioarsinous acid (DMMTAIII ), monomethylmonothioarsonic acid (MMMTAV ),
dimethylmonothioarsinic acid (DMMTAV ) and dimethyldithioarsinic acid (DMDTAV ) suggest the importance of these As metabolites in terms of cellular toxicity and therapeutic
effects [55–57]. DMMTAV is the most cytotoxic thioarsenic radical, similar to DMAIII
in mammals [58]. Since the effects of thioarsenic exposure on human health are controversial, analytical and diagnostic methods for thioarsenicals are urgently needed.
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human body for several months or even longer. As-chelating agents such as BAL, DMPS and DMSA
are frequently used for clinical and therapeutic purposes against acute As exposure and toxicity.
Note: iAsIII , inorganic trivalent arsenic; iAsV , inorganic pentavalent arsenic; MMAIII , monomethylarsonous acid; DMAIII , dimethylarsinous acid; MMAV , methyl arsonate; DMAV , dimethyl arsenate; MMMTAIII , monomethylmonothioarsonous acid; DMMTAIII , dimethylmonothioarsinous acid;
MMMTAV , monomethylmonothioarsonic acid; DMMTAV , dimethylmonothioarsinic acid; DMDTAV ,
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dimethyldithioarsinic acid; SAM—MT, S-adenosylmethionine-dependent methyltrasferase; GSH,
glutathione; Pit, low-affinity, high-capacity phosphate transporter; Pst, high-affinity, low-capacity
phosphate transporter; GlpF, glycerol facilitator protein; AqpS, aquaporin S, Fps1p, yeast aquaglyceroporin; AQP7/9, aquaporin 7/9; HxP, hexose permease, Glut1/2, glucose transporter 1/2, MRP2,
multidrug-resistance-associated protein 2; cMOAT, canalicular-multispecific organic anion transporter 1; ABCC2, ATP-binding cassette sub-family C member 2; BAL, 2,3-dimercaptopropanol; DMPS,
2-3-dimercapto-1-propanesulfonate; DMSA, meso 2,3-dimercaptosuccinic acid. The order of As
species in terms of their cytotoxicity levels was organized by referring to the previous publications
(see main text). The blue, red, black and green arrows indicate methylation, thiolation, reduction and
oxidation processes, respectively.

3. Effects of as on Lipid Metabolism and Adipocyte Function
As accumulates in various tissues in the body, including liver, lung, brain, heart,
kidney, eye and spleen tissues [62]. Chronic exposure to high levels of As has been associated with metabolic diseases such as cardiovascular diseases, hepatotoxicity, diabetes,
obesity and cancers [17,63]. Lipid metabolism plays an important role in chronic diseases
and metabolic syndrome [64,65]. A 15-year birth cohort study showed that early-life
As exposure caused higher atherogenic low-density lipoprotein (LDL) cholesterol levels in
Taiwanese adolescents [66]. As induced dyslipidemia and hypercholesterolemia in male
albino rats after 12 weeks of 150 mg/L (ppm) As exposure in drinking water [67], but
this study used a very high dose and would be expected to be associated with acute liver
toxicity. This would not be relevant to chronic effects in humans at environmental exposure levels—even at relatively high exposure levels. As inhibited high-density lipoprotein
(HDL) cholesterol and increased plasma-free fatty acids. The expression levels of cholesterol metabolism genes, including sterol regulatory element-binding protein 1 (Srebp1c),
3-hydroxy-3-methylglutaryl-CoA reductase (Hmgcr) and cytochrome P450 family 7 subfamily A member 1 (Cyp7a1), were significantly decreased in the liver samples of mice exposed
to 0.25 ppm As in drinking water for two weeks [68]. In addition, serum cholesterol and
lipid levels were significantly increased in mice treated with 1 ppm As for two weeks [68].
Furthermore, lipid peroxidation was increased in the brains of rats exposed to 25 ppm of
As compared to the control group, suggesting that As induced ROS production in the rat
brain [69]. High-dose exposure of As also disrupts lipid metabolism in the adult zebrafish
liver, as revealed by decreased mRNA expression of carnitine O-octanoyl transferase (Crot)
and 3-hydroxy-e-methylglutaryl-CoA synthase 1 (Hmgcs1) and increased mRNA expression of fatty acid binding protein-3 (FABP3) [70]. As exposure promotes atherosclerosis
in the aorta of rats by decreasing the HDL cholesterol/LDL cholesterol ratio [71]. The level
of an indicator of lipid peroxidation, malondialdehyde (MDA), was increased in the serum
of rats exposed to 3 ppm As in drinking water throughout development until the adult
stage [72]. Additionally, serum adiponectin, triglyceride and HDL cholesterol levels were
significantly decreased in mice after 18 weeks of exposure to 50 ppm As in their drinking
water [73]. Collectively, these studies demonstrate that As can affect lipid metabolism
as well as cholesterol metabolism at acute high-dose exposure levels.
As plays a role in adipocyte differentiation and adipose tissue dysfunction and lipodystrophy [74]. As inhibited adipogenesis and glucose uptake in various adipocyte cell types,
including 3T3-L1 preadipocytes, mouse-adipose-derived stromal vascular fraction cells and
human adipose tissue-derived stem cells [75]. The level of mitochondrial oxidative stress
response protein, sirtuin (Sirt) 3, was decreased in As-treated 3T3-L1 adipocytes and C2C12
myotubes, leading to mitochondrial damage [76]. Moreover, the expression levels of Sirt3
targets, including manganese superoxide dismutase (MnSOD) and peroxisome-proliferatoractivated receptor-gamma coactivator (PGC)-1α, were decreased in As-treated 3T3-L1 and
C2C12 cells, indicating that As regulates ROS and its related metabolism in adipocytes [76].
As also inhibits the differentiation of C3H10T1/2 mouse adipose stem cells, resulting in
inhibition of lipid accumulation [77]. Chronic exposure to As reduces the adipose tissue
expression of perilipin (PLIN1), which regulates lipid storage and lipolysis [78]. More-
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as a food source [81–84]. Arsenite-induced oxidative stress induced autophagy as a defense
mechanism in chicken muscle [85]. In a mouse study, up to 0.5 ppm of As trioxide (As2 O3 )
caused myoatrophic effects with decreased muscle mass and endurance [86]. In a recent
human study, muscular atrophy was observed as a side effect in acute promyelocytic
leukemia patients treated with As trioxide [87]. While this study used doses of As that
exceeded those found in environmental exposure, this is important to acknowledge because
it shows the connection between As and muscle atrophy in a human model. Arsenic
exposure increases the reductions in skeletal muscle mass [88] and increases the genetic
risk factors in muscle atrophy and cardiovascular disease [89] in humans. A chronic
low-dose As treatment (0.25–1 µM of As trioxide) causes C2C12 myotube atrophy by
inhibiting the AKT pathway [90]. Since humans consume low doses of As chronically
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through As-contaminated food sources such as fish and chicken, a quantitative analysis of
As accumulation in skeletal muscle in humans and how those chronically accumulated As
exposures can affect the glucose metabolism in muscle tissue is required.
As exposure inhibits myogenesis by inhibiting the β-catenin pathway [91]. As interferes with gluconeogenesis in muscle by inhibiting glucose transporters and suppressing
regulatory genes in glucose metabolism [92]. Thus, As can substantially interfere with
glycolytic and mitochondrial energy generation. However, the exact mechanism explaining
the function of As as an antagonist or synergist in glucose homeostasis in muscle tissue remains to be understood. Biologically relevant oxidation states of As, namely trivalent (AsIII )
and pentavalent (AsV ) forms, are interconvertible and detoxified through methylation in
mammals [93,94]. Both oxidation states may have different chemistries and interactions
with glucose metabolism and energy metabolism pathways in adipose and muscle tissues,
although the relevance of As metabolism in adipose and muscle tissues with human health
outcomes requires further study. While As poisoning and exposure may seem to be a rare
and relatively insignificant issue, in reality hundreds of millions of people are chronically
exposed to elevated levels of As [95] through contaminated drinking water [96], crops and
livestock [97]. This chronic exposure can cause a substantial disease burden in exposed
populations [98], with a prevalence of As-mediated disease directly relating to the level
of exposure [95]. It is worthy of note that there is a threshold for As-related diseases. One
study suggests that the low exposure range of iAs over 150 ppb would increase the risk
of lung and bladder cancers [99]. Large epidemiology studies in Japan and the USA show
no increased risk of cardiovascular disease with even lower exposure levels of iAs under
100 ppb related to amount of rice consumed, the grain with the highest As levels [100].
There are no threshold data available for human studies in metabolic disease, such as
obesity and diabetes, meaning the levels of chronic iAs contamination required to influence
the emergence of these diseases in a population could be much lower than for cancer.
In addition to impacting a host of biological systems, an important aspect of
As-mediated disease is its ability to mimic the symptoms of diabetes through the interactions with glucose metabolism [101]. In vitro studies have demonstrated that treatment
with sub-toxic levels (1 mM, Table 1) of AsIII , in both its inorganic and metabolized monoand di-methyl species, significantly reduced insulin mediated glucose uptake in 3T3-L1
adipocytes by interfering with the localization of insulin-responsive glucose transporter
4 (Glut 4) to the cell membrane [102]. Additional in vitro studies found that longer term
exposure of 3T3-L1 adipocytes to lower levels of inorganic AsIII (iAsIII ) significantly reduced insulin-mediated glucose uptake in levels as low as 0.5 µM [76]. These findings are
recapitulated in in vivo mouse models [101], and additional studies indicate that AsIII may
inhibit the secretion of insulin from pancreatic cells [103]. A proposed mechanism for the
reduced insulin secretion is via the inhibition of mitochondrial metabolism in pancreatic
β-cells [104]. A prospective cohort in humans exposed to very high As levels indicated that
the diabetes risk increased by 3% for every 1 ppb of As present in drinking water [105].
In 2001, the USA Environmental Protection Agency (EPA) revised the acceptable level of
As in drinking water down from 50 ppb to 10 ppb. As is also capable of directly impairing
glucose metabolism. Some evidence suggests that inorganic AsV (iAsV ) can directly interact with glycolytic pathways via substitution with phosphate [106], although this study
was conducted using only enzymes and substrates and required iAsV to be at twice the
concentration of phosphate to observe any effect, while arsenate levels would never be
that high in vivo as that would be lethal, so the biological significance of As on glycolysis
is not clear.
Clearer evidence exists relating As to mitochondrial dysfunction. When isolated rat mitochondria were incubated with 10 to 100 µM of iAsIII , mitochondrial respiratory complexes
I and II were inhibited, leading to excess ROS production, membrane potential collapse
and release of cytochrome c [107]. These findings were reproduced with in vivo rat studies
of chronic As exposure, inhibiting the activity of complexes I, II and IV [108,109], while the
mRNA levels of mitochondrial genes in complexes I and IV were downregulated following
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chronic As exposure [109]. In vivo studies in rats exposed to levels of As commonly found
in contaminated drinking water for 30 days found significantly reduced activity levels of
several key enzymes of the citric acid cycle, including isocitrate dehydrogenase (ICDH)
and succinate dehydrogenase (SDH) [108]. The inhibition of mitochondrial complexes
following As exposure has important implications, as the ROS produced by As-exposed
mitochondria has been shown to be the major route of As-mediated mutagenesis at cytotoxic concentration (0.25 µg/mL, Table 1) [110]. Thus, the generation of mitochondrial
ROS by As can be linked to the role of As as a carcinogen [111]. Most of the current cell
culture and animal experiments used lethal concentrations (Table 1 shows the doses and
durations of As administration). Nearly all of the mitochondrial effects of As are at acutely
toxic, poisonous and lethal concentrations. While these studies were conducted at high As
concentrations, they provide valuable insight into the basic mechanisms of how chronic
lower level As exposure might cause or worsen metabolic diseases.
As exposure also poses important implications for muscle function. Mice exposed
to 100 ppb of iAsIII for five weeks showed decreased muscle function, damage to muscle
progenitor cells and a significant increase in non-phosphorylating LEAK respiration [112].
This indicates that the reduced muscle performance stemming from As may be a result
of mitochondrial abnormalities. As is further implicated in muscle damage by inhibiting
muscle repair, increasing nuclear factor kappa light-chain enhancer of activated B cells
(NF- κB) inflammation signaling and resulting in increased healing time and fibrosis [113].
In addition to direct damage to muscle by As, the tendency for As to mimic diabetes can
also impact muscle tissue [114]. Muscle atrophy can stem directly from the neuropathy
caused by diabetes [115], and a reduction in isometric muscle performance was observed in
diabetic patients during hyperglycemia [116]. Diabetes is also associated with an increase in
intramuscular fat storage, which is in turn associated with reduced muscle strength [117].
In summary, As is associated with significant alterations to glucose metabolism and
mitochondrial function with clear ability to deleteriously impact skeletal muscle function.
A better understanding of how environmental As can impact muscle metabolism and
function would be essential for developing a therapeutic method for humans
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5. Effects of as on Autophagy in Adipose and Muscle Tissues

Several studies indicated that As is known to have detrimental effects on adipose and
muscle tissues of fish, animals, livestock, experimental rodents and humans, as discussed
above. In the case of adipose tissue, many research groups have already evaluated the
effects of As using various adipocytes such as 3T3-L1, 3T3-F442A, C3H 10T1/2, HIB1B and
so on [77,79,118–121] (Table 1). Additionally, several animal experiments were also
performed with As exposure [17,79,118] (Table 1). Most of these studies showed the
inhibitory effects of As administration on the growth and differentiation of the adipocytes.
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5. Effects of as on Autophagy in Adipose and Muscle Tissues
Several studies indicated that As is known to have detrimental effects on adipose and
muscle tissues of fish, animals, livestock, experimental rodents and humans, as discussed
above. In the case of adipose tissue, many research groups have already evaluated the
effects of As using various adipocytes such as 3T3-L1, 3T3-F442A, C3H 10T1/2, HIB1B
and so on [77,79,118–121] (Table 1). Additionally, several animal experiments were also
performed with As exposure [17,79,118] (Table 1). Most of these studies showed the
inhibitory effects of As administration on the growth and differentiation of the adipocytes.
Although many genes and signaling pathways have been suggested as possible causes,
including peroxisome-proliferator-activated receptor gamma (PPARγ), CCAAT/enhancerbinding protein-alpha (C/EBPα), cyclin-dependent kinase inhibitor 1A (p21), protein
kinase B (Akt/PKB), sirtuin 3 (SIRT3)-forkhead box O3 (FOXO3a), mitogen-activated
protein kinase (MAPK) cascade and C/EBP homologous protein (CHOP10)-G protein
coupled receptor (GPCR) pathways, the role of As in adipose tissue remains unclear [17,74].
Muscle is also known to be another target tissue of As exposure, although this is much less
studied even than adipose tissue. One study showed that the levels of glucose transporters
1 and 4 (GLUT1/4) and activation of inositol phospholipid 3-kinase (PI3K) increased
with 0.5 mM As treatment in L6 rat skeletal muscle cells [118,122]. In our previous study,
we observed the accumulation of As in a dose-dependent manner in mouse adipose
tissue [79]. However, in the case of muscle tissue, another study reported that there was
no As accumulation in muscle tissue when mice were exposed to As [17,112]. Although
As did not accumulate in the muscle tissue of mice, they found impaired muscle function
and increased mitochondrial oxygen consumption through the isolated primary muscle
cells from mice after As exposure of 100 µg/L for 5 weeks [112]. Interestingly, in our
previous studies, we also measured the oxygen consumption rate in response to highdose As treatment in adipocytes (10 µM) and in adipose tissue of mice (10 mg/kg/d).
However, the oxygen consumption was significantly decreased in the adipocytes when
the treated As concentration was increased, and there was no difference in mice when
compared with the control group [79]. The working mechanisms of As in adipose and
muscle tissues are unique, presumably due to sensitivity to As and differences in cellular
adaptivity regarding As accumulation. Muscle weakness is a major factor contributing to
decreased functional mobility and is a strong predictor of mortality. Muscle weakness and
wasting are also some of the most common pathologic clinical symptoms of environmental
exposure to As [86,88]. However, the mechanisms and molecular pathogenesis in the
etiology of As-induced muscle morbidity are relatively unknown. In addition, although
the contribution of As exposure to stem cell function is important for development and
has been increasingly investigated, there is an unmet need to know whether and how
environmental toxicants such as As affect adult stem cell behavior. It is important to resolve
how stem cell vulnerability to environmental contaminants affects the ability of otherwise
healthy tissues to respond to acute injury. An enhanced understanding of the mechanisms
underlying the clinical symptoms of skeletal muscle dysfunction induced by As is crucial
for the design of strategies and policies to prevent or reduce muscle injury.
Autophagy, a topic of the 2016 Nobel Prize in Physiology or Medicine [123], is one
of the major cellular degradation systems as a catabolic process of lysosomes for cellular
life preservation [124–126]. Degenerated proteins, organelles and cytoplasmic wastes
are removed by the autophagy system [127]. The objects for removal are isolated in the
vesicles called autophagosomes, which form double-membraned structures in the cells.
After the vesicle is combined with the lysosomes, autophagolysosomes are formed and
then degraded by lysosomal enzymes [128,129]. The degraded materials are used to make
energy for cell survival or to generate new organelles [130]. Thus, autophagy is a substantial
intracellular recycling system that is used to protect cells from the accumulated toxic
proteins and to maintain intracellular homeostasis [124]. Autophagy defects have been
implicated in various metabolic diseases and cancer [131,132]. Autophagy is also necessary
for proper differentiation of adipose tissue [133], and obese patients showed an abnormally
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high level of autophagy gene expression in white adipose tissue analyzed via bariatric
surgery [134]. This could be a compensatory effect from the deficiency in autophagy
activity and the elevation of the apoptosis pathway in obese patients [135,136]. Autophagy
promotes muscle wasting and sarcopenia, a loss of muscle mass upon aging, because of
protein breakdown. However, autophagy actually maintains muscle mass and protects
against age-related muscle degeneration and dysfunction [137]. Increased basal autophagy
protects against sarcopenia by degrading misfolded proteins and organelles. Although
there are strong correlations between autophagy and metabolism, there is a knowledge gap
on how autophagy regulates lipid and glucose metabolism in adipose and muscle tissues.
It is already well known that autophagy is closely connected in adipogenesis through
studies in autophagy-deficient cell lines and mouse models, such as Atg5 and Atg7 knockouts [138]. Although impaired autophagy function from the embryo stage was fatal in mice
after birth [139], in another sense autophagy-related gene knockout mice showed antiobesity and antidiabetic phenotypes in adipocytes [138]. Ironically, this depends on the conditions, but autophagy shows ambivalence. Although there is a lack of definitive research
supporting the causal relationship between autophagy and As in adipose and muscle tissues, it has been shown that there is a close correlation between As toxicity and autophagy
function [79,85,140,141]. In one research group, the upregulated autophagy-related proteins
such as microtubule-associated protein 1 light chain 3 (LC3)-II and sequestosome 1 (p62)
were observed in mouse skeletal muscle upon As exposure (4 µM or 4 mg/L in drinking
water for 12 weeks) [141]. In another study, the accumulated As (Table 1) in chicken skeletal
muscle induced intracellular oxidative damage and was linked to the autophagy activation by PI3K–AKT–mechanistic target of rapamycin kinase (mTOR) pathway inhibition
and mitochondrial dysfunction [85,140]. In our previous studies, we also showed that As
exposure induced oxidative stress and suppressed adipogenesis and mitochondrial biogenesis, respiration and thermogenesis via autophagy inhibition in adipocyte cell culture and
adipose tissue of mice. The cause of the autophagy inhibition by As was associated with
the suppressed sestrin-2 (SESN2) and unc-51-like autophagy-activating kinase 1 (ULK1)
in BAT of mice [79].
The acute exposure to As trioxide (50 µM for 24 h) induced autophagy as a result
of blocking the apoptosis pathway in H9c2 rat cardiomyoblastoma cells [142]. Acute
autophagy induction in As exposure in mammalian cells is known to be significantly
induced by ROS [143]. Contrary to studies in cardiomyocytes, multiple studies have
demonstrated autophagy inhibition by As in NIH3T3 fibroblasts. One study reported that
short-term treatment of 1 µM As for 4 h began to block autophagy flux by activating the Nrf2
pathway in a p62-dependent manner in NIH3T3 fibroblasts [144]. Another study observed
that 2 µM As (III) treatment up to 48 h caused autophagy dysfunction by inhibiting SNARE
complex formation in NIH3T3 fibroblasts [145].
We have summarized the effects of As exposure on autophagy induction and function in adipose and muscle tissues. Although autophagy activation or inhibition by As
is dependent on the As dose and length of treatment, cell type and mouse species, chronic
As accumulation beyond the physiological threshold leads to autophagy dysregulation
accompanied by an impaired antioxidant defense system, damaged intracellular organelles
with metabolic dysfunction and unbalanced metabolic homeostasis in adipose and muscle
tissues. Thus, autophagy dysregulation caused by chronic As exposure in adipose and
muscle tissues contributes to the development of metabolic disease in humans (Figure 4).
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a poison as well as a medicine, highlighting that the right amount of As in treatment
could be beneficial for human health. In that sense, we could not exclude the possibility that chronic low-dose (less than 10 ppb) As exposure in adipose and muscle tissues
would be beneficial as a hormesis effect for inducing the oxidative defense mechanism
or inhibiting apoptosis differently from the harmful effects of high-dose As exposure in
the liver, urinary tract, lungs and skin. In this review, we have summarized the effects
of As exposure on metabolism and autophagy in adipose and muscle tissues, which are
major target tissues in metabolic syndrome. Although the effects of acute and chronic As
exposure have identified action mechanisms in adipose and muscle tissues, the effects of
indirect As exposure from food or directly from the environment remain controversial and
require further research in the USA. In conclusion, studies on the effects of As in metabolic
function and in autophagy activity in adipose and muscle tissues could be beneficial for
the group of people who are suffering from metabolic syndrome and diseases in highly
As-contaminated areas worldwide.
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Table 1. Summary of the maximum dose and duration of As treated or administered in the research
papers that are referenced in this review.
Samples

Cell
culture

Dose and Duration of As

Reference

3T3-L1 preadipocytes,
mouse-adipose-derived stromal
vascular fraction cells and human
adipose tissue-derived stem cells

5 µM (sodium arsenite), 1 µM (trivalent
monomethylated arsenic), or 2 µM
(trivalent dimethylated arsenic) in
medium, 2 days with DMI
(differentiation media)

[75]

3T3-L1 adipocytes

1 mM, sodium arsenite (NaAsO2 ),
methylarsine oxide and
iododimethylarsine in medium, until
full differentiation for several days

[102]

3T3-L1

3 µM, arsenic trioxide (As2 O3 ) in
medium, during differentiation for 24 h

[119]

3T3-F442A

0.5 µM/L, arsenic trioxide in medium,
3 days

[120]

Adipose-tissue-derived primary
human mesenchymal stem cells
(hMSCs)

1 µM, sodium arsenite in medium, 72 h

[78]

C2C12 myoblast cells and 3T3-L1

2 µM, sodium arsenite in medium,
8 weeks

[76]

C2C12 myotubules

1 µM, arsenic trioxide in medium, 48 h

[90]

C3H 10T1/2 adipocytes

6 µM, sodium arsenite in medium,
2 months

[77,121]

EJ-1, human bladder cancer cells

Up to 1 mM (iASIII , iASV , MMAV ,
MMMTAV , DMAV , DMAIII ,DMMTAV
or DMDTAV ) in medium, 24 h

[58]

H9c2 rat cardiomyoblastoma cells

50 µM, arsenic trioxide in medium, 24 h

[142]

HaCaT human keratinocytes

25 µM, sodium arsenite in medium,
24 h

[35]

HEK293, NIH3T3, BEAS-2B

1 µM, sodium arsenite in medium, 24 h

[144]

HIB1B adipocytes

10 µM, sodium arsenite in medium,
6 days

[79]

Human–hamster hybrid AL cells

0.25 µg/mL, sodium arsenite in
medium, 60 days

[110]

INS-1 832/13 beta cells

2 µM (sodium arsenite, dimethyl
arsenite), 0.5 µM (mono-methyl
arsenite) in medium, 24 h

[104]

L6 rat skeletal muscle cells

0.5 mM, sodium arsenite in medium,
30 min

[123]

NIH3T3, HeLa cells

2 µM, sodium arsenite in medium, 48 h

[145]

P19 mouse embryonic stem cells

1 µM, sodium arsenite in medium,
5 days until full differentiation

[91]

PAEC, porcine aortic endothelial cells

5 µM, sodium arsenite in medium, 2 h

[32]

Pancreatic eyelets (ex vivo) of B6 mice

0.1 µM (methylarsonite,
dimethylarsinite) in medium, 48 h

[103]

Primary SECs, Liver sinusoidal
endothelial cells

5 µM, sodium arsenite in medium, 8 h

[33]

UROtsa, Non-tumorigenic human
urothelial cell lines

1 µM, sodium arsenite in medium,
12 weeks
50 nM, MMA (III) in medium, 24 weeks

[36]
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Table 1. Cont.
Samples

Animals

Dose and Duration of As

Reference

Chicken skeletal muscle (in vivo)

2.5 mg/kg/day, until reach 30 mg/kg,
H3 AsO3 in diet

[85]

Chickens

2.5 mg/kg, As2 O3 in diet, 12 weeks

[140]

Hamster LD50

112 µmol/kg and 29.3 µmol/kg
(MMAIII ) in diet

[42]

Mice (C57BL/6 aka B6, male and
female)

10 mg/kg/d, sodium arsenite in
gavage, 9 days

[79]

Mice (B6, male)

45 ppm, sodium arsenite in drinking
water, 48 weeks

[34]

Mice (B6, male)

50 ppm, sodium arsenite in drinking
water, 18 weeks

[73]

Mice (B6, male)

50 ppm, sodium arsenate in drinking
water, 8 weeks

[101]

Mice (B6, female)

20 ppm, sodium arsenite and sodium
arsenate dibasic heptahydrate (1:1
ratio) in drinking water, 17 weeks

[80]

Mice (C57BL/6J, male) eye

250 ppm for 1 month or 50 ppm for 6
months (sodium arsenite) in
drinking water

[62]

Mice (B6) skeletal muscle

4 µM or 4 mg/L, arsenic trioxide in
drinking water, 12 weeks

[141]

Mice (C57BL/6Tac)

100 µg/L, sodium arsenite in drinking
water, 5 weeks

[78]

Mice (C57BL/6Tac)

100 µg/L, trivalent arsenite (AsIII) in
drinking water, 5 weeks

[112]

Mice (C57BL/6NTac male)

100 µg/L, sodium metaarsenite
(NaAsO2 ) in drinking water, 5 weeks

[113]

Mice (C57BL/6Ai p47phox knockout)

250 ppb, sodium arsenite in drinking
water, 2 weeks

[33]

Mice (CrL:Sk1-hrBD, weanling female
hairless mice) skin

5 mg/L, sodium arsenite in drinking
water, 26 weeks

[46]

Mice (sciatic nerve denervated)

0.5 ppm, arsenic trioxide in drinking
water, 4 weeks

[86]

Mice (specific pathogen free female)

1 ppm, sodium arsenite in drinking
water, 2 weeks

[68]

Rat (Winstar, Albino male)

150 ppm (sodium arsenite), 200 ppm
(sodium arsenate) in drinking water,
12 weeks

[67]

Rat (Albino male)

25 ppm, sodium arsenite in drinking
water, 8 weeks

[69]

Rat (Albino male)

133 µg/mL (arsenic trioxide) in
drinking water, 8 weeks

[71]

Rat (Albino pregnant)

13 ppm, sodium arsenite, from
gestation, lactation through full
adulthood in drinking water

[72]

Rat liver tissue in test tube

40 µM sodium arsenate uptake upto
30 min

[106]

Rat liver mitochondria

100 µM, sodium arsenite, 5 min

[107]
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Table 1. Cont.
Samples

Human
patients

Dose and Duration of As

Reference

Rat liver mitochondria

25 ppm, sodium arsenite, 12 weeks

[109]

Rat (Winstar, TR− )

0.5 mg/kg, 1 mmol, 0.4 mmol (MMA),
1 mmol (DMA), injection through bile
duct cannulation less than 5 s

[50]

Zebrafish

500 ppb, sodium arsenite in water,
7 days

[70]

Arsenic biomarkers in human

1–2 mg/kg (LD50 of iAs), accumulated
arsenic from food, water, air and soil

[29]

Hair, nails and skin scales of
arsenic-exposed patients in West
Bengal, India

Arsenic patients exposed to above 50
mg/L in drinking groundwater

[44]

Human (2–14 years old adolescents)
arsenicosis patients

Upto 31.6 µg/L total inorganic arsenic
exposure, upto 14 years

[66]

Human acute promyelocytic leukaemia
(APL) patients

All patients were treated with
intravenous infusion of 10 mg of As2 O3
(10 mL, 0.1% solution) over 2–8 h daily
for 28 d and the cycle was repeated at
intervals of 2 weeks until complete
remission (CR) was achieved. After CR,
they were maintained with several
cycles of As2 O3 at intervals of
2–3 months.

[87]

Human cardiovascular disease patients

100 µg/L of arsenic above or below in
meta-analysis

[95]

Human patients (arsenic exposure)

Chronic exposure of arsenic in
Bandladeshi (above 10 µg/L exposure)
for 9 days

[98]

Human patients (Diabetes)

Geographical tracing (0.1 µg/L
detection limit of arsenic) in Denmark
for mean follow-up for 9.7 years

[105]
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Kloska, A.; W˛esierska, M.; Malinowska, M.; Gabig-Cimińska, M.; Jakóbkiewicz-Banecka, J. Lipophagy and Lipolysis Status in
Lipid Storage and Lipid Metabolism Diseases. Int. J. Mol. Sci. 2020, 21, 6113. [CrossRef] [PubMed]
Kuo, C.C.; Su, P.H.; Sun, C.W.; Liu, H.J.; Chang, C.L.; Wang, S.L. Early-life arsenic exposure promotes atherogenic lipid metabolism
in adolescence: A 15-year birth cohort follow-up study in central Taiwan. Environ. Int. 2018, 118, 97–105. [CrossRef] [PubMed]
Afolabi, O.K.; Wusu, A.D.; Ogunrinola, O.O.; Abam, E.O.; Babayemi, D.O.; Dosumu, O.A.; Onunkwor, O.B.; Balogun, E.A.;
Odukoya, O.O.; Ademuyiwa, O. Arsenic-induced dyslipidemia in male albino rats: Comparison between trivalent and pentavalent inorganic arsenic in drinking water. BMC Pharm. Toxicol. 2015, 16, 15. [CrossRef] [PubMed]
Chi, L.; Lai, Y.; Tu, P.; Liu, C.W.; Xue, J.; Ru, H.; Lu, K. Lipid and Cholesterol Homeostasis after Arsenic Exposure and Antibiotic
Treatment in Mice: Potential Role of the Microbiota. Environ. Health Perspect 2019, 127, 97002. [CrossRef] [PubMed]
Soni, M.; Prakash, C.; Dabur, R.; Kumar, V. Protective Effect of Hydroxytyrosol Against Oxidative Stress Mediated by ArsenicInduced Neurotoxicity in Rats. Appl Biochem. Biotechnol. 2018, 186, 27–39. [CrossRef] [PubMed]
Carlson, P.; Van Beneden, R.J. Arsenic exposure alters expression of cell cycle and lipid metabolism genes in the liver of adult
zebrafish (Danio rerio). Aquat. Toxicol. 2014, 153, 66–72. [CrossRef] [PubMed]
Cheng, T.J.; Chuu, J.J.; Chang, C.Y.; Tsai, W.C.; Chen, K.J.; Guo, H.R. Atherosclerosis induced by arsenic in drinking water in rats
through altering lipid metabolism. Toxicol. Appl. Pharm. 2011, 256, 146–153. [CrossRef]
Rivas-Santiago, C.; Gonzalez-Curiel, I.; Zarazua, S.; Murgu, M.; Ruiz Cardona, A.; Lazalde, B.; Lara-Ramirez, E.E.; Vazquez, E.;
Castaneda-Delgado, J.E.; Rivas-Santiago, B.; et al. Lipid Metabolism Alterations in a Rat Model of Chronic and Intergenerational
Exposure to Arsenic. Biomed. Res. Int. 2019, 2019, 4978018. [CrossRef]
Song, X.; Li, Y.; Liu, J.; Ji, X.; Zhao, L.; Wei, Y. Changes in Serum Adiponectin in Mice Chronically Exposed to Inorganic Arsenic in
Drinking Water. Biol. Trace Elem. Res. 2017, 179, 140–147. [CrossRef]
Renu, K.; Madhyastha, H.; Madhyastha, R.; Maruyama, M.; Arunachlam, S.; V G, A. Role of arsenic exposure in adipose tissue
dysfunction and its possible implication in diabetes pathophysiology. Toxicol. Lett. 2018, 284, 86–95. [CrossRef]
Hou, Y.; Xue, P.; Woods, C.G.; Wang, X.; Fu, J.; Yarborough, K.; Qu, W.; Zhang, Q.; Andersen, M.E.; Pi, J. Association between
arsenic suppression of adipogenesis and induction of CHOP10 via the endoplasmic reticulum stress response. Environ. Health
Perspect 2013, 121, 237–243. [CrossRef] [PubMed]
Padmaja Divya, S.; Pratheeshkumar, P.; Son, Y.O.; Vinod Roy, R.; Andrew Hitron, J.; Kim, D.; Dai, J.; Wang, L.; Asha, P.; Huang, B.;
et al. Arsenic Induces Insulin Resistance in Mouse Adipocytes and Myotubes Via Oxidative Stress-Regulated Mitochondrial
Sirt3-FOXO3a Signaling Pathway. Toxicol. Sci. 2015, 146, 290–300. [CrossRef] [PubMed]
Trouba, K.J.; Wauson, E.M.; Vorce, R.L. Sodium arsenite inhibits terminal differentiation of murine C3H 10T1/2 preadipocytes.
Toxicol. Appl. Pharm. 2000, 168, 25–35. [CrossRef] [PubMed]
Garciafigueroa, D.Y.; Klei, L.R.; Ambrosio, F.; Barchowsky, A. Arsenic-stimulated lipolysis and adipose remodeling is mediated
by G-protein-coupled receptors. Toxicol. Sci. 2013, 134, 335–344. [CrossRef]
Bae, J.; Jang, Y.; Kim, H.; Mahato, K.; Schaecher, C.; Kim, I.M.; Kim, E.; Ro, S.H. Arsenite exposure suppresses adipogenesis,
mitochondrial biogenesis and thermogenesis via autophagy inhibition in brown adipose tissue. Sci. Rep. 2019, 9, 14464. [CrossRef]
Zuo, Z.; Liu, Z.; Gao, T.; Yin, Y.; Wang, Z.; Hou, Y.; Fu, J.; Liu, S.; Wang, H.; Xu, Y.; et al. Prolonged inorganic arsenic exposure via
drinking water impairs brown adipose tissue function in mice. Sci. Total Environ. 2019, 668, 310–317. [CrossRef]
Chiesa, L.M.; Ceriani, F.; Procopio, A.; Bonacci, S.; Malandra, R.; Panseri, S.; Arioli, F. Exposure to metals and arsenic from yellow
and red tuna consumption. Food Addit. Contam. Part A Chem Anal. Control. Expo. Risk Assess. 2019, 36, 1228–1235. [CrossRef]
Farzad, R.; Kuhn, D.D.; Smith, S.A.; O’Keefe, S.F.; Ralston, N.V.C.; Neilson, A.P.; Gatlin, D.M. Trace minerals in tilapia fillets:
Status in the United States marketplace and selenium supplementation strategy for improving consumer’s health. PLoS ONE
2019, 14, e0217043. [CrossRef]

Antioxidants 2022, 11, 689

83.
84.
85.
86.
87.

88.

89.

90.
91.
92.
93.
94.
95.

96.
97.

98.

99.
100.
101.

102.
103.
104.
105.

106.
107.
108.
109.

18 of 20

Pei, J.; Zuo, J.; Wang, X.; Yin, J.; Liu, L.; Fan, W. The Bioaccumulation and Tissue Distribution of Arsenic Species in Tilapia. Int. J.
Environ. Res. Public Health 2019, 16, 757. [CrossRef]
Szymkowicz, D.B.; Schwendinger, K.L.; Tatnall, C.M.; Swetenburg, J.R.; Bain, L.J. Embryonic-only arsenic exposure alters skeletal
muscle satellite cell function in killifish (Fundulus heteroclitus). Aquat. Toxicol. 2018, 198, 276–286. [CrossRef]
Wang, Y.; Zhao, H.; Shao, Y.; Liu, J.; Li, J.; Luo, L.; Xing, M. Copper (II) and/or arsenite-induced oxidative stress cascades
apoptosis and autophagy in the skeletal muscles of chicken. Chemosphere 2018, 206, 597–605. [CrossRef] [PubMed]
Chen, C.M.; Chung, M.N.; Chiu, C.Y.; Liu, S.H.; Lan, K.C. Inorganic Arsenic Exposure Decreases Muscle Mass and Enhances
Denervation-Induced Muscle Atrophy in Mice. Molecules 2020, 25, 3057. [CrossRef] [PubMed]
Huang, S.Y.; Chang, C.S.; Tang, J.L.; Tien, H.F.; Kuo, T.L.; Huang, S.F.; Yao, Y.T.; Chou, W.C.; Chung, C.Y.; Wang, C.H.; et al. Acute
and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia. Br. J. Haematol. 1998, 103, 1092–1095.
[CrossRef] [PubMed]
Sarker, M.K.; Tony, S.R.; Siddique, A.E.; Karim, M.R.; Haque, N.; Islam, Z.; Islam, M.S.; Khatun, M.; Islam, J.; Hossain, S.; et al.
Arsenic Secondary Methylation Capacity Is Inversely Associated with Arsenic Exposure-Related Muscle Mass Reduction. Int. J.
Environ. Res. Public Health 2021, 18, 9730. [CrossRef] [PubMed]
Rehman, M.Y.A.; Briede, J.J.; van Herwijnen, M.; Krauskopf, J.; Jennen, D.G.J.; Malik, R.N.; Kleinjans, J.C.S. Integrating SNPsbased genetic risk factor with blood epigenomic response of differentially arsenic-exposed rural subjects reveals disease-associated
signaling pathways. Environ. Pollut. 2022, 292, 118279. [CrossRef] [PubMed]
Chiu, C.Y.; Chung, M.N.; Lan, K.C.; Yang, R.S.; Liu, S.H. Exposure of low-concentration arsenic induces myotube atrophy by
inhibiting an Akt signaling pathway. Toxicol. Vitr. 2020, 65, 104829. [CrossRef] [PubMed]
Hong, G.M.; Bain, L.J. Arsenic exposure inhibits myogenesis and neurogenesis in P19 stem cells through repression of the
beta-catenin signaling pathway. Toxicol. Sci. 2012, 129, 146–156. [CrossRef]
Diaz-Villasenor, A.; Burns, A.L.; Hiriart, M.; Cebrian, M.E.; Ostrosky-Wegman, P. Arsenic-induced alteration in the expression of
genes related to type 2 diabetes mellitus. Toxicol. Appl. Pharm. 2007, 225, 123–133. [CrossRef]
Drobna, Z.; Styblo, M.; Thomas, D.J. An Overview of Arsenic Metabolism and Toxicity. Curr. Protoc. Toxicol. 2009. [CrossRef]
Hughes, M.F. Arsenic toxicity and potential mechanisms of action. Toxicol. Lett. 2002, 133, 1–16. [CrossRef]
Moon, K.A.; Oberoi, S.; Barchowsky, A.; Chen, Y.; Guallar, E.; Nachman, K.E.; Rahman, M.; Sohel, N.; D’Ippoliti, D.; Wade, T.J.;
et al. A dose-response meta-analysis of chronic arsenic exposure and incident cardiovascular disease. Int. J. Epidemiol. 2017, 46,
1924–1939. [CrossRef] [PubMed]
Fisher, A.T.; López-Carrillo, L.; Gamboa-Loira, B.; Cebrián, M.E. Standards for arsenic in drinking water: Implications for policy
in Mexico. J. Public Health Policy 2017, 38, 395–406. [CrossRef] [PubMed]
Carlin, D.J.; Naujokas, M.F.; Bradham, K.D.; Cowden, J.; Heacock, M.; Henry, H.F.; Lee, J.S.; Thomas, D.J.; Thompson, C.;
Tokar, E.J.; et al. Arsenic and Environmental Health: State of the Science and Future Research Opportunities. Environ. Health
Perspect. 2016, 124, 890–899. [CrossRef] [PubMed]
Argos, M.; Kalra, T.; Rathouz, P.J.; Chen, Y.; Pierce, B.; Parvez, F.; Islam, T.; Ahmed, A.; Rakibuz-Zaman, M.; Hasan, R.; et al.
Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): A prospective
cohort study. Lancet 2010, 376, 252–258. [CrossRef]
Shao, K.; Zhou, Z.; Xun, P.; Cohen, S.M. Bayesian benchmark dose analysis for inorganic arsenic in drinking water associated
with bladder and lung cancer using epidemiological data. Toxicology 2021, 455, 152752. [CrossRef]
Sidhu, M.S.; Desai, K.P.; Lynch, H.N.; Rhomberg, L.R.; Beck, B.D.; Venditti, F.J. Mechanisms of action for arsenic in cardiovascular
toxicity and implications for risk assessment. Toxicology 2015, 331, 78–99. [CrossRef]
Paul, D.S.; Hernandez-Zavala, A.; Walton, F.S.; Adair, B.M.; Dedina, J.; Matousek, T.; Styblo, M. Examination of the effects of
arsenic on glucose homeostasis in cell culture and animal studies: Development of a mouse model for arsenic-induced diabetes.
Toxicol. Appl. Pharm. 2007, 222, 305–314. [CrossRef]
Walton, F.S.; Harmon, A.W.; Paul, D.S.; Drobna, Z.; Patel, Y.M.; Styblo, M. Inhibition of insulin-dependent glucose uptake by
trivalent arsenicals: Possible mechanism of arsenic-induced diabetes. Toxicol. Appl. Pharm. 2004, 198, 424–433. [CrossRef]
Douillet, C.; Currier, J.; Saunders, J.; Bodnar, W.M.; Matousek, T.; Styblo, M. Methylated trivalent arsenicals are potent inhibitors
of glucose stimulated insulin secretion by murine pancreatic islets. Toxicol. Appl. Pharm. 2013, 267, 11–15. [CrossRef]
Dover, E.N.; Beck, R.; Huang, M.C.; Douillet, C.; Wang, Z.; Klett, E.L.; Styblo, M. Arsenite and methylarsonite inhibit mitochondrial
metabolism and glucose-stimulated insulin secretion in INS-1 832/13 beta cells. Arch. Toxicol. 2018, 92, 693–704. [CrossRef]
Brauner, E.V.; Nordsborg, R.B.; Andersen, Z.J.; Tjonneland, A.; Loft, S.; Raaschou-Nielsen, O. Long-term exposure to low-level
arsenic in drinking water and diabetes incidence: A prospective study of the diet, cancer and health cohort. Environ. Health
Perspect. 2014, 122, 1059–1065. [CrossRef] [PubMed]
Crane, R.K.; Lipmann, F. The effect of arsenate on aerobic phosphorylation. J. Biol. Chem. 1953, 201, 235–243. [CrossRef]
Hosseini, M.J.; Shaki, F.; Ghazi-Khansari, M.; Pourahmad, J. Toxicity of Arsenic (III) on Isolated Liver Mitochondria: A New
Mechanistic Approach. Iran. J. Pharm Res. 2013, 12, 121–138. [PubMed]
Ramanathan, K.; Shila, S.; Kumaran, S.; Panneerselvam, C. Ascorbic acid and α-tocopherol as potent modulators on arsenic
induced toxicity in mitochondria. J. Nutr. Biochem. 2003, 14, 416–420. [CrossRef]
Prakash, C.; Kumar, V. Chronic Arsenic Exposure-Induced Oxidative Stress is Mediated by Decreased Mitochondrial Biogenesis
in Rat Liver. Biol. Trace Elem. Res. 2016, 173, 87–95. [CrossRef]

Antioxidants 2022, 11, 689

19 of 20

110. Partridge, M.A.; Huang, S.X.; Hernandez-Rosa, E.; Davidson, M.M.; Hei, T.K. Arsenic induced mitochondrial DNA damage
and altered mitochondrial oxidative function: Implications for genotoxic mechanisms in mammalian cells. Cancer Res. 2007, 67,
5239–5247. [CrossRef]
111. Martinez, V.D.; Vucic, E.A.; Becker-Santos, D.D.; Gil, L.; Lam, W.L. Arsenic Exposure and the Induction of Human Cancers.
J. Toxicol. 2011, 2011, 1–13. [CrossRef]
112. Ambrosio, F.; Brown, E.; Stolz, D.; Ferrari, R.; Goodpaster, B.; Deasy, B.; Distefano, G.; Roperti, A.; Cheikhi, A.; Garciafigueroa, Y.;
et al. Arsenic induces sustained impairment of skeletal muscle and muscle progenitor cell ultrastructure and bioenergetics. Free
Radic. Biol. Med. 2014, 74, 64–73. [CrossRef]
113. Zhang, C.; Ferrari, R.; Beezhold, K.; Stearns-Reider, K.; D’Amore, A.; Haschak, M.; Stolz, D.; Robbins, P.D.; Barchowsky, A.;
Ambrosio, F. Arsenic Promotes NF-Kappab-Mediated Fibroblast Dysfunction and Matrix Remodeling to Impair Muscle Stem Cell
Function. Stem. Cells 2016, 34, 732–742. [CrossRef]
114. D’Souza, D.M.; Al-Sajee, D.; Hawke, T.J. Diabetic myopathy: Impact of diabetes mellitus on skeletal muscle progenitor cells.
Front. Physiol. 2013, 4, 379. [CrossRef]
115. Andersen, H.; Gjerstad, M.D.; Jakobsen, J. Atrophy of Foot Muscles: A measure of diabetic neuropathy. Diabetes Care 2004, 27,
2382–2385. [CrossRef] [PubMed]
116. Andersen, H.; Schmitz, O.; Nielsen, S. Decreased isometric muscle strength after acute hyperglycaemia in Type 1 diabetic patients.
Diabet Med. 2005, 22, 1401–1407. [CrossRef] [PubMed]
117. Hilton, T.N.; Tuttle, L.J.; Bohnert, K.L.; Mueller, M.J.; Sinacore, D.R. Excessive Adipose Tissue Infiltration in Skeletal Muscle in
Individuals With Obesity, Diabetes Mellitus, and Peripheral Neuropathy: Association With Performance and Function. Phys. Ther.
2008, 88, 1336–1344. [CrossRef] [PubMed]
118. Navas-Acien, A.; Silbergeld, E.K.; Streeter, R.A.; Clark, J.M.; Burke, T.A.; Guallar, E. Arsenic exposure and type 2 diabetes: A
systematic review of the experimental and epidemiological evidence. Environ. Health Perspect. 2006, 114, 641–648. [CrossRef]
119. Wang, Z.X.; Jiang, C.S.; Liu, L.; Wang, X.H.; Jin, H.J.; Wu, Q.; Chen, Q. The role of Akt on arsenic trioxide suppression of 3T3-L1
preadipocyte differentiation. Cell Res. 2005, 15, 379–386. [CrossRef]
120. Salazard, B.; Bellon, L.; Jean, S.; Maraninchi, M.; El-Yazidi, C.; Orsière, T.; Margotat, A.; Botta, A.; Bergé-Lefranc, J.L. Low-level
arsenite activates the transcription of genes involved in adipose differentiation. Cell Biol. Toxicol. 2004, 20, 375–385. [CrossRef]
121. Wauson, E.M.; Langan, A.S.; Vorce, R.L. Sodium arsenite inhibits and reverses expression of adipogenic and fat cell-specific genes
during in vitro adipogenesis. Toxicol. Sci. 2002, 65, 211–219. [CrossRef]
122. McDowell, H.E.; Walker, T.; Hajduch, E.; Christie, G.; Batty, I.H.; Downes, C.P.; Hundal, H.S. Inositol phospholipid 3-kinase is
activated by cellular stress but is not required for the stress-induced activation of glucose transport in L6 rat skeletal muscle cells.
Eur. J. Biochem. 1997, 247, 306–313. [CrossRef]
123. Levine, B.; Klionsky, D.J. Autophagy wins the 2016 Nobel Prize in Physiology or Medicine: Breakthroughs in baker’s yeast fuel
advances in biomedical research. Proc. Natl. Acad. Sci. USA 2017, 114, 201–205. [CrossRef]
124. Mizushima, N.; Komatsu, M. Autophagy: Renovation of cells and tissues. Cell 2011, 147, 728–741. [CrossRef]
125. Blasiak, J.; Pawlowska, E.; Chojnacki, J.; Szczepanska, J.; Chojnacki, C.; Kaarniranta, K. Zinc and Autophagy in Age-Related
Macular Degeneration. Int. J. Mol. Sci. 2020, 21, 4994. [CrossRef] [PubMed]
126. Galluzzi, L.; Baehrecke, E.H.; Ballabio, A.; Boya, P.; Bravo-San Pedro, J.M.; Cecconi, F.; Choi, A.M.; Chu, C.T.; Codogno, P.;
Colombo, M.I.; et al. Molecular definitions of autophagy and related processes. EMBO J. 2017, 36, 1811–1836. [CrossRef]
[PubMed]
127. Pallauf, K.; Rimbach, G. Autophagy, polyphenols and healthy ageing. Ageing Res. Rev. 2013, 12, 237–252. [CrossRef] [PubMed]
128. Noda, N.N.; Inagaki, F. Mechanisms of Autophagy. Annu. Rev. Biophys. 2015, 44, 101–122. [CrossRef]
129. Galluzzi, L.; Pietrocola, F.; Levine, B.; Kroemer, G. Metabolic control of autophagy. Cell 2014, 159, 1263–1276. [CrossRef]
130. Rabinowitz, J.D.; White, E. Autophagy and metabolism. Science 2010, 330, 1344–1348. [CrossRef]
131. Levine, B.; Kroemer, G. Autophagy in the pathogenesis of disease. Cell 2008, 132, 27–42. [CrossRef]
132. Mizushima, N.; Levine, B.; Cuervo, A.M.; Klionsky, D.J. Autophagy fights disease through cellular self-digestion. Nature 2008,
451, 1069–1075. [CrossRef]
133. Ahmed, M.; Nguyen, H.Q.; Hwang, J.S.; Zada, S.; Lai, T.H.; Kang, S.S.; Kim, D.R. Systematic characterization of autophagy-related
genes during the adipocyte differentiation using public-access data. Oncotarget 2018, 9, 15526–15541. [CrossRef]
134. Kovsan, J.; Bluher, M.; Tarnovscki, T.; Kloting, N.; Kirshtein, B.; Madar, L.; Shai, I.; Golan, R.; Harman-Boehm, I.; Schon, M.R.;
et al. Altered autophagy in human adipose tissues in obesity. J. Clin. Endocrinol. Metab. 2011, 96, E268–E277. [CrossRef]
135. Kosacka, J.; Kern, M.; Kloting, N.; Paeschke, S.; Rudich, A.; Haim, Y.; Gericke, M.; Serke, H.; Stumvoll, M.; Bechmann, I.; et al.
Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol. Cell. Endocrinol. 2015, 409, 21–32. [CrossRef]
[PubMed]
136. Soussi, H.; Reggio, S.; Alili, R.; Prado, C.; Mutel, S.; Pini, M.; Rouault, C.; Clement, K.; Dugail, I. DAPK2 Downregulation
Associates With Attenuated Adipocyte Autophagic Clearance in Human Obesity. Diabetes 2015, 64, 3452–3463. [CrossRef]
[PubMed]
137. Jiao, J.; Demontis, F. Skeletal muscle autophagy and its role in sarcopenia and organismal aging. Curr. Opin. Pharm. 2017, 34, 1–6.
[CrossRef] [PubMed]
138. Zhang, Y.; Zeng, X.; Jin, S. Autophagy in adipose tissue biology. Pharm. Res 2012, 66, 505–512. [CrossRef] [PubMed]

Antioxidants 2022, 11, 689

20 of 20

139. Baerga, R.; Zhang, Y.; Chen, P.H.; Goldman, S.; Jin, S. Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a
cellular model and in mice. Autophagy 2009, 5, 1118–1130. [CrossRef]
140. Wang, Y.; Zhao, H.; Shao, Y.; Liu, J.; Li, J.; Luo, L.; Xing, M. Copper or/and arsenic induces autophagy by oxidative stress-related
PI3K/AKT/mTOR pathways and cascaded mitochondrial fission in chicken skeletal muscle. J. Inorg. Biochem. 2018, 188, 1–8.
[CrossRef]
141. Yang, L.; Qiu, T.; Yao, X.; Jiang, L.; Wei, S.; Pei, P.; Wang, Z.; Bai, J.; Liu, X.; Yang, G.; et al. Taurine protects against arsenic
trioxide-induced insulin resistance via ROS-Autophagy pathway in skeletal muscle. Int. J. Biochem. Cell Biol. 2019, 112, 50–60.
[CrossRef]
142. Bessho, M.; Aki, T.; Funakoshi, T.; Unuma, K.; Noritake, K.; Kato, C.; Uemura, K. Rho-kinase inhibitor Y-27632 attenuates arsenic
trioxide toxicity in H9c2 cardiomyoblastoma cells. Cardiovasc. Toxicol. 2013, 13, 267–277. [CrossRef]
143. Azad, M.B.; Chen, Y.; Gibson, S.B. Regulation of autophagy by reactive oxygen species (ROS): Implications for cancer progression
and treatment. Antioxid. Redox. Signal. 2009, 11, 777–790. [CrossRef]
144. Lau, A.; Zheng, Y.; Tao, S.; Wang, H.; Whitman, S.A.; White, E.; Zhang, D.D. Arsenic inhibits autophagic flux, activating the
Nrf2-Keap1 pathway in a p62-dependent manner. Mol. Cell Biol. 2013, 33, 2436–2446. [CrossRef]
145. Dodson, M.; Liu, P.; Jiang, T.; Ambrose, A.J.; Luo, G.; Rojo de la Vega, M.; Cholanians, A.B.; Wong, P.K.; Chapman, E.; Zhang, D.D.
Increased O-GlcNAcylation of SNAP29 Drives Arsenic-Induced Autophagic Dysfunction. Mol. Cell Biol. 2018, 38, e00595-17.
[CrossRef] [PubMed]
146. Vahidnia, A.; van der Voet, G.B.; de Wolff, F.A. Arsenic neurotoxicity—A review. Hum. Exp. Toxicol. 2007, 26, 823–832. [CrossRef]
[PubMed]
147. Liu, J.; Lu, Y.; Wu, Q.; Goyer, R.A.; Waalkes, M.P. Mineral arsenicals in traditional medicines: Orpiment, realgar, and arsenolite.
J. Pharm. Exp. 2008, 326, 363–368. [CrossRef]
148. Au, W.Y. A biography of arsenic and medicine in Hong Kong and China. Hong Kong Med. J. 2011, 17, 507–513. [PubMed]
149. Waxman, S.; Anderson, K.C. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001, 6 (Suppl. 2),
3–10. [CrossRef] [PubMed]

